Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma

References

• de G, Gores G, LaRusso N, Gunderson L, Nagorney D. Biliary tract cancers. N. Engl. J. Med.341(18), 1368–1378 (1999).
   PubMed Web of Science ®Google Scholar
• Greene FL, Compton CC; American Joint Committee on Cancer. AJCC Cancer Staging Atlas. Fritz AG (Ed.). Springer Verlag, USA (2006).
   Google Scholar
• Khan S, Davidson B, Goldin R et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut51(Suppl. 6), VI1–VI9 (2002).
   PubMedGoogle Scholar
• Kondo S, Takada T, Miyazaki M et al. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J. Hepatobiliary Pancreat. Surg.15(1), 41–54 (2008).
   PubMedGoogle Scholar
• Hezel A, Zhu A. Systemic therapy for biliary tract cancers. Oncologist13(4), 415–423 (2008).
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med.362(14), 1273–1281 (2010).
   PubMed Web of Science ®Google Scholar
• Valle JW, Wasan H, Johnson P et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised Phase II study – the UK ABC-01 Study. Br. J. Cancer101(4), 621–627 (2009).
   PubMed Web of Science ®Google Scholar
• Bengala C, Bertolini F, Malavasi N et al. Sorafenib in patients with advanced biliary tract carcinoma: a Phase II trial. Br. J. Cancer102(1), 68–72 (2010).
   PubMed Web of Science ®Google Scholar
• LaRocca R, Hicks M, Mull L, Foreman B. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. J. Gastrointest. Cancer38(2–4), 154–156 (2007).
   PubMedGoogle Scholar
• Philip PA, Mahoney MR, Allmer C et al. Phase II study of erlotinib in patients with advanced biliary cancer. J. Clin. Oncol.24(19), 3069–3074 (2006).
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Belani CP, Singh DA et al. A Phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother. Pharmacol.64(4), 777–783 (2009).
   PubMed Web of Science ®Google Scholar
• Rizell M, Andersson M, Cahlin C et al. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int. J. Clin. Oncol.13(1), 66–70 (2008).
   PubMed Web of Science ®Google Scholar
• Castroagudín JF, Molina E, Tomé S et al. Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence. Transplant Proc.41(3), 1003–1004 (2009).
   PubMed Web of Science ®Google Scholar
• Holcombe RF, Gu M, Imagawa D, Milovanovic T. Expression of Kit and platelet-derived growth factor receptors α and β in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571). Anticancer Drugs14(8), 651–657 (2003).
   PubMed Web of Science ®Google Scholar
• Wiedmann M, Mössner J. Molecular targeted therapy of biliary tract cancer: results of the first clinical studies. Curr. Drug Targets11(7), 834–850 (2010).
   PubMed Web of Science ®Google Scholar
• Ho C, Sangha R, Beckett L et al. Escalating weekly doses of cetuximab and correlation with skin toxicity: a Phase I study. Invest. New Drugs DOI: 10.1007/s10637-010-9396-4 (2010) (Epub ahead of print).
   Google Scholar
• Propper DJ, McDonald AC, Man A et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J. Clin. Oncol.19(5), 1485–1492 (2001).
   PubMed Web of Science ®Google Scholar
• Lubner SJ, Mahoney MR, Kolesar JL et al. Report of a multicenter Phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a Phase II Consortium study. J. Clin. Oncol.28(21), 3491–3497 (2010).
   PubMed Web of Science ®Google Scholar
• Abbruzzese JL, Levin B, Ajani JA et al. Phase I trial of recombinant human γ-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res.49(14), 4057–4061 (1989).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351(4), 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Patt YZ, Jones DV, Hoque A et al. Phase II trial of intravenous flourouracil and subcutaneous interferon α-2b for biliary tract cancer. J. Clin. Oncol.14(8), 2311–2315 (1996).
   PubMed Web of Science ®Google Scholar
• Patt YZ, Hassan MM, Lozano RD et al. Phase II trial of cisplatin, interferon α-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin. Cancer Res.7(11), 3375–3380 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu AX, Meyerhardt JA, Blaszkowsky LS et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a Phase 2 study. Lancet Oncol.11(1), 48–54 (2010).
   PubMed Web of Science ®Google Scholar
• Tai CJ, Chiou HY, Wu CH, Pan S, Liu JD. Rapid resolution of liver metastasis from cholangiocarcinoma after bevacizumab with cisplatin and high-dose fluorouracil plus leucovorin. Onkologie29(4), 179–180 (2006).
   PubMedGoogle Scholar
• Paule B, Herelle MO, Rage E et al. Cetuximab plus gemcitabine–oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology72(1–2), 105–110 (2007).
   PubMed Web of Science ®Google Scholar
• Chang PY, Cheng MF, Lee HS, Hsieh CB, Yao NS. Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer. Onkologie33(1–2), 45–47 (2010).
   PubMed Web of Science ®Google Scholar
• Huang TW, Wang CH, Hsieh CB. Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver. Onkologie30(3), 129–131 (2007).
   PubMedGoogle Scholar
• Sprinzl M, Schimanski C, Moehler M et al. Gemcitabine in combination with EGF-receptor antibody (cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC Cancer6, 190 (2006).
   PubMed Web of Science ®Google Scholar
• Bralet MP, Bellin MF, Guettier C, Adam R, Paule B. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma. Clin. Oncol. (R. Coll. Radiol.)18(5), 426 (2006).
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Atmaca A, Schleyer E et al. Imatinib mesylate for targeting the platelet-derived growth factor β receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer: a dose-escalation Phase I trial. Cancer109(9), 1897–1904 (2007).
   PubMed Web of Science ®Google Scholar
• Safran H, Miner T, Resnick M et al. Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a Phase I study for advanced pancreaticobiliary cancer. Am. J. Clin. Oncol.31(2), 140–144 (2008).
   PubMed Web of Science ®Google Scholar
• Siegel-Lakhai W, Beijnen J, Vervenne W et al. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clin. Cancer Res.13(15 Pt 1), 4495–4502 (2007).
   PubMed Web of Science ®Google Scholar
• Richly H, Kupsch P, Passage K et al. Results of a Phase I trial of BAY 43–9006 in combination with doxorubicin in patients with primary hepatic cancer. Int. J. Clin. Pharmacol. Ther.42(11), 650–651 (2004).
   PubMedGoogle Scholar
• Qun W, Tao Y. Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China. Hepatogastroenterology57(99–100), 426–429 (2010).
   PubMedGoogle Scholar
• Recchia F, Sica G, Candeloro G et al. Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter Phase II study. Pancreas38(6), e163–e168 (2009).
   Google Scholar
• Watkins JF, Mayo MS, Smith HJ, Williamson SK. Gemcitabine, irinotecan and celecoxib in patients with biliary cancer. Anticancer Drugs20(4), 294–300 (2009).
   PubMed Web of Science ®Google Scholar
• Pino MS, Milella M, Gelibter A et al. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology76(4), 254–261 (2009).
   PubMed Web of Science ®Google Scholar
• Lam ET, O’Bryant CL, Basche M et al. A Phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Mol. Cancer Ther.7(12), 3685–3694 (2008).
   PubMed Web of Science ®Google Scholar
• Soeda A, Morita-Hoshi Y, Kaida M et al. Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites. Jpn J. Clin. Oncol.40(12), 1184–1188 (2010).
   PubMed Web of Science ®Google Scholar
• Dragovich T, Huberman M, Von Hoff DD et al. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: Phase IB trial. Cancer Chemother. Pharmacol.60(2), 295–303 (2007).
   PubMed Web of Science ®Google Scholar
• Messersmith W, Baker S, Lassiter L et al. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin. Cancer Res.12(4), 1270–1275 (2006).
   PubMed Web of Science ®Google Scholar
• Malka D, Trarbach T, Fartoux L et al. A multicenter, randomized Phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial. J. Clin. Oncol.(Meeting Abstracts)27(15S), 4520 (2009).
   Google Scholar
• Gruenberger B, Schueller J, Kaczirek K et al. Efficacy results of cetuximab plus gemcitabine–oxaliplatin (GEMOX) in patients with advanced or metastatic cholangiocarcinoma: a single centre Phase II study. J. Clin. Oncol.(Meeting Abstracts)26(15 Suppl.), 4586 (2008).
   Google Scholar
• Gruenberger B, Schueller J, Tamandl D et al. K-ras status and response in patients with advanced or metastatic cholangiocarcinoma treated with cetuximab plus gemcitabine–oxaliplatin (GEMOX): a single center Phase II study. J. Clin. Oncol.(Meeting Abstracts)27(15S), 4586 (2009).
   Google Scholar
• Bekaii-Saab T, Phelps M, Li X et al. A multi-institutional study of AZD6244 (ARRY-142886) in patients with advanced biliary cancers. Proc. Am. Assoc. Cancer Res. 2009(Apr), LB 129 (2009).
   Google Scholar
• El-Khoueiry A, Rankin C, Lenz H et al. SWOG 0514: a Phase II study of sorafenib (BAY 43–9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. J. Clin. Oncol.(Meeting Abstracts)25(18 Suppl.), 4639 (2007).
   Google Scholar
• Costello M, Meropol N, Denlinger C et al. A Phase II trial of the proteasome inhibitor bortezomib in patients with recurrent or metastatic adenocarcinoma of the bile duct or gallbladder (NCI #6135). J. Clin. Oncol.(Meeting Abstracts)27(15S), e15605 (2009).
   Google Scholar
• Buzzoni R, Pusceddu S, Platania M et al. Efficacy and safety of RAD001 in advanced biliary tract cancer (BTC) patients (pts) progressing after first-line chemotherapy: a Phase II study. J. Clin. Oncol.(Meeting Abstracts)28(15 Suppl.), e14500 (2010).
   Google Scholar
• Olesen R, Rohrberg K, Ladekarl M et al. A Phase II study of erlotinib and bevacizumab in patients with advanced upper gastrointestinal (GI) cancers refractory to chemotherapy. 2009 Gastrointestinal Cancers Symposium (2009) (Abstract 170).
   Google Scholar
• Limentani S, Just R, Purdham A et al. A Phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: rreliminary results. J. Clin. Oncol.(Meeting Abstracts)26(15 Suppl.), 3556 (2008).
   Google Scholar
• Kaida M, Morita-Hoshi Y, Wakeda T et al. Phase I trial of gemcitabine and Wilms’ tumor 1 peptide vaccine combination therapy in patients with advanced pancreatic or biliary tract cancer. J. Clin. Oncol.(Meeting Abstracts)28(15 Suppl.), e13049 (2010).
   Google Scholar
• Ettinger D, Finkelstein D, Abeloff M et al. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J. Natl Cancer Inst.84(14), 1077–1084 (1992).
   PubMedGoogle Scholar
• Dhani N, Tu D, Sargent D, Seymour L, Moore M. Alternate endpoints for screening Phase II studies. Clin. Cancer Res.15(6), 1873–1882 (2009).
   PubMed Web of Science ®Google Scholar
• Ratain M, Sargent D. Optimising the design of Phase II oncology trials: the importance of randomisation. Eur. J. Cancer.45(2), 275–280 (2009).
   PubMed Web of Science ®Google Scholar
• Rubinstein L, Korn E, Freidlin B et al. Design issues of randomized Phase II trials and a proposal for Phase II screening trials. J. Clin. Oncol.23(28), 7199–7206 (2005).
   PubMed Web of Science ®Google Scholar
• Allegra C, Jessup J, Somerfield M et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol.27(12), 2091–2096 (2009).
   PubMed Web of Science ®Google Scholar